Comparison of recurrence patterns between patients with thoracic esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy and postoperative adjuvant chemoradiotherapy
PurposeTo compare the recurrence patterns and survival outcomes between patients with esophageal squamous cell carcinoma (ESCC) treated with neoadjuvant chemoradiotherapy (NCRT) and adjuvant chemoradiotherapy (ACRT).MethodsWe retrospectively analyzed 267 patients with locally advanced ESCC who recei...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-06-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1604808/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849694114606481408 |
|---|---|
| author | Kunhan Ni Kunhan Ni Yixuan Huang Simiao Lu Longlin Jiang Huan Zhang Wenwu He Chenghao Wang Qiang Zhou Haojun Li Jialong Li Kangning Wang Guangyuan Liu Qiang Fang Lin Peng Xuefeng Leng Yongtao Han Yongtao Han |
| author_facet | Kunhan Ni Kunhan Ni Yixuan Huang Simiao Lu Longlin Jiang Huan Zhang Wenwu He Chenghao Wang Qiang Zhou Haojun Li Jialong Li Kangning Wang Guangyuan Liu Qiang Fang Lin Peng Xuefeng Leng Yongtao Han Yongtao Han |
| author_sort | Kunhan Ni |
| collection | DOAJ |
| description | PurposeTo compare the recurrence patterns and survival outcomes between patients with esophageal squamous cell carcinoma (ESCC) treated with neoadjuvant chemoradiotherapy (NCRT) and adjuvant chemoradiotherapy (ACRT).MethodsWe retrospectively analyzed 267 patients with locally advanced ESCC who received treatment at Sichuan Cancer Hospital and Institute (Chengdu, China) between January 2018 and December 2020. Based on different treatment protocols, the patients were divided into two groups: NCRT (n=181) and ACRT (n=86). After propensity score matching, each group included 74 patients. This study compared the recurrence types, sites, frequencies, and timing, as well as overall survival (OS), disease-free survival (DFS), and prognostic risk factors between the two groups.ResultsThe recurrence rates in the NCRT and ACRT groups were 59.5% (44/74) and 33.8% (25/74), respectively; the difference was statistically significant (P=0.002). Recurrences primarily occurred within 2 years following esophagectomy. The ACRT group had a higher 3-year OS rate than the NCRT group (67.8% versus [vs.] 50.6%, respectively; P=0.019). In the subgroup of patients with local recurrence, the 3-year OS rate was higher in the NCRT group compared to the ACRT group (53.8% vs. 0%, respectively; P=0.029). In terms of DFS, the ACRT group exhibited better results than the NCRT group (P<0.001). Multivariate analysis revealed that pathological N staging was an independent risk factor affecting the OS prognosis of patients in the NCRT group. Margin status and pathological T staging were identified as independent risk factors influencing OS in the ACRT group, while sex and treatment regimen were independent risk factors affecting DFS in patients with postoperative pathological lymph node positivity.ConclusionThere was significant difference in the OS and DFS prognosis of patients with ESCC treated with NCRT and ACRT. Recurrence primarily occurs within 2 years following esophagectomy. The recurrence rate was higher in the NCRT group compared to the ACRT group. Patients with early recurrence had a poorer survival prognosis compared to those with late recurrence. Pathological N staging was identified as an independent risk factor affecting OS in the NCRT group. Furthermore, margin status and pathological T staging were independent risk factors influencing OS in the ACRT group. |
| format | Article |
| id | doaj-art-2c6dfbd9e93047b8a7e7791bc9dfdc00 |
| institution | DOAJ |
| issn | 2234-943X |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-2c6dfbd9e93047b8a7e7791bc9dfdc002025-08-20T03:20:12ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-06-011510.3389/fonc.2025.16048081604808Comparison of recurrence patterns between patients with thoracic esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy and postoperative adjuvant chemoradiotherapyKunhan Ni0Kunhan Ni1Yixuan Huang2Simiao Lu3Longlin Jiang4Huan Zhang5Wenwu He6Chenghao Wang7Qiang Zhou8Haojun Li9Jialong Li10Kangning Wang11Guangyuan Liu12Qiang Fang13Lin Peng14Xuefeng Leng15Yongtao Han16Yongtao Han17Department of Thoracic Surgery, the Affiliated Hospital of Southwest Medical University, Sichuan, Luzhou, ChinaDepartment of Thoracic Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China (UESTC), Chengdu, ChinaDepartment of Thoracic Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China (UESTC), Chengdu, ChinaDepartment of Thoracic Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China (UESTC), Chengdu, ChinaDepartment of Thoracic Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China (UESTC), Chengdu, ChinaDepartment of Thoracic Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China (UESTC), Chengdu, ChinaDepartment of Thoracic Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China (UESTC), Chengdu, ChinaDepartment of Thoracic Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China (UESTC), Chengdu, ChinaDepartment of Thoracic Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China (UESTC), Chengdu, ChinaDepartment of Thoracic Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China (UESTC), Chengdu, ChinaDepartment of Thoracic Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China (UESTC), Chengdu, ChinaDepartment of Thoracic Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China (UESTC), Chengdu, ChinaDepartment of Thoracic Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China (UESTC), Chengdu, ChinaDepartment of Thoracic Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China (UESTC), Chengdu, ChinaDepartment of Thoracic Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China (UESTC), Chengdu, ChinaDepartment of Thoracic Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China (UESTC), Chengdu, ChinaDepartment of Thoracic Surgery, the Affiliated Hospital of Southwest Medical University, Sichuan, Luzhou, ChinaDepartment of Thoracic Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China (UESTC), Chengdu, ChinaPurposeTo compare the recurrence patterns and survival outcomes between patients with esophageal squamous cell carcinoma (ESCC) treated with neoadjuvant chemoradiotherapy (NCRT) and adjuvant chemoradiotherapy (ACRT).MethodsWe retrospectively analyzed 267 patients with locally advanced ESCC who received treatment at Sichuan Cancer Hospital and Institute (Chengdu, China) between January 2018 and December 2020. Based on different treatment protocols, the patients were divided into two groups: NCRT (n=181) and ACRT (n=86). After propensity score matching, each group included 74 patients. This study compared the recurrence types, sites, frequencies, and timing, as well as overall survival (OS), disease-free survival (DFS), and prognostic risk factors between the two groups.ResultsThe recurrence rates in the NCRT and ACRT groups were 59.5% (44/74) and 33.8% (25/74), respectively; the difference was statistically significant (P=0.002). Recurrences primarily occurred within 2 years following esophagectomy. The ACRT group had a higher 3-year OS rate than the NCRT group (67.8% versus [vs.] 50.6%, respectively; P=0.019). In the subgroup of patients with local recurrence, the 3-year OS rate was higher in the NCRT group compared to the ACRT group (53.8% vs. 0%, respectively; P=0.029). In terms of DFS, the ACRT group exhibited better results than the NCRT group (P<0.001). Multivariate analysis revealed that pathological N staging was an independent risk factor affecting the OS prognosis of patients in the NCRT group. Margin status and pathological T staging were identified as independent risk factors influencing OS in the ACRT group, while sex and treatment regimen were independent risk factors affecting DFS in patients with postoperative pathological lymph node positivity.ConclusionThere was significant difference in the OS and DFS prognosis of patients with ESCC treated with NCRT and ACRT. Recurrence primarily occurs within 2 years following esophagectomy. The recurrence rate was higher in the NCRT group compared to the ACRT group. Patients with early recurrence had a poorer survival prognosis compared to those with late recurrence. Pathological N staging was identified as an independent risk factor affecting OS in the NCRT group. Furthermore, margin status and pathological T staging were independent risk factors influencing OS in the ACRT group.https://www.frontiersin.org/articles/10.3389/fonc.2025.1604808/fullesophageal squamous cell carcinomaesophagectomychemoradiotherapyrecurrence patternspropensity score matching |
| spellingShingle | Kunhan Ni Kunhan Ni Yixuan Huang Simiao Lu Longlin Jiang Huan Zhang Wenwu He Chenghao Wang Qiang Zhou Haojun Li Jialong Li Kangning Wang Guangyuan Liu Qiang Fang Lin Peng Xuefeng Leng Yongtao Han Yongtao Han Comparison of recurrence patterns between patients with thoracic esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy and postoperative adjuvant chemoradiotherapy Frontiers in Oncology esophageal squamous cell carcinoma esophagectomy chemoradiotherapy recurrence patterns propensity score matching |
| title | Comparison of recurrence patterns between patients with thoracic esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy and postoperative adjuvant chemoradiotherapy |
| title_full | Comparison of recurrence patterns between patients with thoracic esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy and postoperative adjuvant chemoradiotherapy |
| title_fullStr | Comparison of recurrence patterns between patients with thoracic esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy and postoperative adjuvant chemoradiotherapy |
| title_full_unstemmed | Comparison of recurrence patterns between patients with thoracic esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy and postoperative adjuvant chemoradiotherapy |
| title_short | Comparison of recurrence patterns between patients with thoracic esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy and postoperative adjuvant chemoradiotherapy |
| title_sort | comparison of recurrence patterns between patients with thoracic esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy and postoperative adjuvant chemoradiotherapy |
| topic | esophageal squamous cell carcinoma esophagectomy chemoradiotherapy recurrence patterns propensity score matching |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2025.1604808/full |
| work_keys_str_mv | AT kunhanni comparisonofrecurrencepatternsbetweenpatientswiththoracicesophagealsquamouscellcarcinomatreatedwithneoadjuvantchemoradiotherapyandpostoperativeadjuvantchemoradiotherapy AT kunhanni comparisonofrecurrencepatternsbetweenpatientswiththoracicesophagealsquamouscellcarcinomatreatedwithneoadjuvantchemoradiotherapyandpostoperativeadjuvantchemoradiotherapy AT yixuanhuang comparisonofrecurrencepatternsbetweenpatientswiththoracicesophagealsquamouscellcarcinomatreatedwithneoadjuvantchemoradiotherapyandpostoperativeadjuvantchemoradiotherapy AT simiaolu comparisonofrecurrencepatternsbetweenpatientswiththoracicesophagealsquamouscellcarcinomatreatedwithneoadjuvantchemoradiotherapyandpostoperativeadjuvantchemoradiotherapy AT longlinjiang comparisonofrecurrencepatternsbetweenpatientswiththoracicesophagealsquamouscellcarcinomatreatedwithneoadjuvantchemoradiotherapyandpostoperativeadjuvantchemoradiotherapy AT huanzhang comparisonofrecurrencepatternsbetweenpatientswiththoracicesophagealsquamouscellcarcinomatreatedwithneoadjuvantchemoradiotherapyandpostoperativeadjuvantchemoradiotherapy AT wenwuhe comparisonofrecurrencepatternsbetweenpatientswiththoracicesophagealsquamouscellcarcinomatreatedwithneoadjuvantchemoradiotherapyandpostoperativeadjuvantchemoradiotherapy AT chenghaowang comparisonofrecurrencepatternsbetweenpatientswiththoracicesophagealsquamouscellcarcinomatreatedwithneoadjuvantchemoradiotherapyandpostoperativeadjuvantchemoradiotherapy AT qiangzhou comparisonofrecurrencepatternsbetweenpatientswiththoracicesophagealsquamouscellcarcinomatreatedwithneoadjuvantchemoradiotherapyandpostoperativeadjuvantchemoradiotherapy AT haojunli comparisonofrecurrencepatternsbetweenpatientswiththoracicesophagealsquamouscellcarcinomatreatedwithneoadjuvantchemoradiotherapyandpostoperativeadjuvantchemoradiotherapy AT jialongli comparisonofrecurrencepatternsbetweenpatientswiththoracicesophagealsquamouscellcarcinomatreatedwithneoadjuvantchemoradiotherapyandpostoperativeadjuvantchemoradiotherapy AT kangningwang comparisonofrecurrencepatternsbetweenpatientswiththoracicesophagealsquamouscellcarcinomatreatedwithneoadjuvantchemoradiotherapyandpostoperativeadjuvantchemoradiotherapy AT guangyuanliu comparisonofrecurrencepatternsbetweenpatientswiththoracicesophagealsquamouscellcarcinomatreatedwithneoadjuvantchemoradiotherapyandpostoperativeadjuvantchemoradiotherapy AT qiangfang comparisonofrecurrencepatternsbetweenpatientswiththoracicesophagealsquamouscellcarcinomatreatedwithneoadjuvantchemoradiotherapyandpostoperativeadjuvantchemoradiotherapy AT linpeng comparisonofrecurrencepatternsbetweenpatientswiththoracicesophagealsquamouscellcarcinomatreatedwithneoadjuvantchemoradiotherapyandpostoperativeadjuvantchemoradiotherapy AT xuefengleng comparisonofrecurrencepatternsbetweenpatientswiththoracicesophagealsquamouscellcarcinomatreatedwithneoadjuvantchemoradiotherapyandpostoperativeadjuvantchemoradiotherapy AT yongtaohan comparisonofrecurrencepatternsbetweenpatientswiththoracicesophagealsquamouscellcarcinomatreatedwithneoadjuvantchemoradiotherapyandpostoperativeadjuvantchemoradiotherapy AT yongtaohan comparisonofrecurrencepatternsbetweenpatientswiththoracicesophagealsquamouscellcarcinomatreatedwithneoadjuvantchemoradiotherapyandpostoperativeadjuvantchemoradiotherapy |